drugset / Trial / NCT05605665
Low-dose Interleukin-2 and Rapamycin on sjögren's Syndrome
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this paper is to analysis of therapeutic effect and immunological mechanism of low-dose IL-2 combined with rapamycin in the treatment of Sjogren's syndrome
Timeline
- Start
- 2022-12-05
- Primary completion
- 2023-12-30
- Completion
- 2024-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sirolimus | Small molecule | 0.5 ml | Oral |
| Subject | aldesleukin | Protein / enzyme biologic | 1e+06 iu | Subcutaneous |